Cardiac Stem Cell Processing via Filtration and Automation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating cardiac stem cells for repairing or regenerating damaged cardiac tissue face challenges in scaling up processing and culturing to produce sufficient quantities for therapeutic use, particularly in allogeneic cardiac stem cell therapy, where large tissue samples require efficient processing and reduced cell clumping to minimize adverse side effects.
Innovation Solution
The methods involve processing donor cardiac tissue into tissue explants, enzymatic digestion, culturing until cells migrate, filtering to remove particles greater than 50 μm, and optimizing culture conditions to generate cardiosphere-derived cells (CDCs) suitable for allogeneic cardiac stem cell therapy, including the use of anti-clumping agents and automated processing to enhance yield and reduce contamination risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If large tissue samples are processed to generate sufficient quantities of cardiac stem cells for therapeutic use, then the quantity of cells produced increases, but cell clumping occurs which causes adverse side effects such as arrhythmia and vascular blockage
Solution Approach 1:
The patent applies filtration to extract and remove cell clumps from the cardiac stem cell suspension. A filter with a specific pore size (e.g., 40 μm) is used to separate individual cells from aggregated clumps, allowing the therapeutic cell suspension to proceed while removing the harmful clumped particles that could cause arrhythmia or vascular blockage
Solution Approach 2:
The patent changes the physical parameter of the cell suspension by controlling cell density and using mechanical agitation or ultrasound treatment to disrupt cell clumping. By adjusting these parameters, the suspension maintains cells in a dispersed state suitable for intracoronary delivery while preserving cell viability and therapeutic potency
2Reliability
If manual processing methods are used for tissue explants, then contamination risk is reduced through careful handling, but processing time and labor requirements increase significantly
Solution Approach 1:
The patent replaces manual mechanical handling with automated mechanical systems for tissue processing. Automated tissue choppers and cutters process the cardiac tissue into explants with consistent size and shape, reducing processing time while maintaining reliability through controlled, sterile automated environments that minimize contamination risk
Solution Approach 2:
The patent uses porous filtration membranes with defined pore sizes to separate cells from tissue debris during processing. These porous filters allow efficient separation while maintaining sterile barriers, enabling faster processing compared to manual centrifugation or filtration methods
3Quantity of substance
If enzymatic digestion is used to release cells from tissue explants, then cell yield increases, but cell viability may be reduced due to excessive enzyme exposure
Solution Approach 1:
The patent applies periodic or pulsed enzymatic digestion rather than continuous exposure. The tissue explants are incubated with enzymes (such as collagenase or dispase) for specific time intervals, then the enzymes are removed or inactivated. This periodic treatment allows sufficient cell release while preventing excessive digestion that would damage cell membranes and reduce viability
Solution Approach 2:
The patent uses protective intermediaries during enzymatic digestion, such as serum-containing buffers or specific enzyme inhibitors, to modulate the enzymatic activity. These intermediaries allow the enzymes to effectively release cells from the tissue matrix while protecting the cell surfaces from excessive enzymatic damage, thereby maintaining cell viability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of high-quality, filtered CDCs that can be administered via intracoronary delivery, reducing risks of adverse side effects such as arrhythmia and vascular blockage, while maintaining the therapeutic potency and consistency of the cardiac stem cell therapy.
Implementation Method 1
enzymatically digesting the explants
Implementation Method 2
filtering the harvested CDCs to remove particles greater than about 50 μm
Data Source
AI summary
The present disclosure relates generally to methods for the increased processing of tissue for the generation of cardiac stem cells, wherein the stem cells are suitable for use in cardiac stem cell therapy. In particular, several embodiments relate to the processing of allogeneic donor cardiac tissue for the generation of multiple patient doses of cardiac stem cells.